|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma IAPP concentrations were elevated in the patients with pancreatic cancer as compared with the normal subjects (mean [+/- SD], 22.3 +/- 13.6 vs. 8.0 +/- 5.0 pmol per liter; P < 0.001), normal in the patients with other cancers, and normal or low in the patients with diabetes.
|
8277951 |
1994 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IAPP amyloid oligomers are biomarkers of the onset and progression of diabetes and could play a role as therapeutic targets.
|
28912603 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This short review provides a brief introduction to amylin biology, the use of an amylin analog to treat diabetes, and consideration of whether amylin could have any role in headache disorders.
|
28485843 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analogs of IAPP have been approved for the treatment of diabetes and are under investigation for the treatment of obesity.
|
23337872 |
2013 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide.
|
9588445 |
1998 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Is islet amyloid polypeptide a significant factor in pathogenesis or pathophysiology of diabetes?
|
1999269 |
1991 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that IAPP-induced beta-cell apoptosis causes defects in insulin secretion and beta-cell mass that lead first to hepatic insulin resistance and IFG and then to extrahepatic insulin resistance, hyperglucagonemia, and diabetes.
|
16804082 |
2006 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mice hemizygous for transgenic expression of human IAPP did not develop diabetes; however, loss of β cell-specific autophagy in these animals induced diabetes, which was attributable to accumulation of toxic human IAPP oligomers and loss of β cell mass.
|
25036708 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A better understanding of how β-cell processing of PI and proIAPP, as well as α-cell processing of proglucagon, are impacted by genetic susceptibility and in the face of diabetogenic stresses, may lead to new therapeutic approaches for improving islet function in diabetes.
|
30230179 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of fibrillogenic human amylin in these human amylin transgenic mice caused beta-cell degeneration and diabetes through mechanisms independent from both peripheral insulin resistance and islet amyloid.
|
18633116 |
2008 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we focus on islet amyloid polypeptide (IAPP) mediated loss-of-insulin secreting cells in patients with diabetes.
|
29615609 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pathological findings and physiological functions of amylin have led to the introduction of pramlintide, an amylin analog, for the treatment of diabetes.
|
30919775 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Islet amyloid polypeptide (IAPP<sub>1-37</sub>) or amylin is implicated in the aetiology of diabetes.
|
30466917 |
2019 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated plasma islet amyloid polypeptide levels have been demonstrated in some diabetic, glucose-intolerant, and obese individuals, as well as in rodent models of diabetes and obesity.
|
7929617 |
1994 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used amylin knockout (AKO) mice intravenously infused with either human amylin (i.e, the aggregated form) or non-amyloidogenic (i.e., monomeric) rodent amylin to test the hypothesis that aggregated amylin accumulates in the heart in the absence of diabetes.
|
29066284 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes.
|
15161755 |
2004 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, many agents targeting the CGRP system are in clinical trials, and pramlintide, an amylin analogue, is an approved therapy for insulin-requiring diabetes.
|
29059473 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, the molecular basis of the huge metabolic benefits in bariatric surgery is emerging while novel incretin-based medicines based on endogenous hormones such as glucagon-like peptide 1 and pancreas-derived amylin are improving diabetes management.
|
28275047 |
2017 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Determine whether plasma levels of precursor forms of IAPP are elevated in diabetes.
|
28368485 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Islet amyloid polypeptide and diabetes.
|
23745697 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Small molecules, including β-sheet breaker peptides, chemical chaperones, and foldamers, inhibit and disaggregate amyloid formed by human amylin, suggesting the possible use of these small molecules in the treatment of diabetes.
|
30082607 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro, and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice.
|
27865831 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pancreatic islet amyloidosis by the hormone IAPP, the production of advanced glycation endproducts (AGE), and insulin misprocessing into cytotoxic aggregates are all sources of β-cell proteotoxicity in diabetes.
|
29664151 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rodent IAPP is not amyloidogenic, thus commonly used rodent models of diabetes do not recapitulate islet pathology in humans.
|
16804197 |
2006 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans.
|
28503657 |
2017 |